- Home
- ANAB vs TIPT Comparison
ANAB vs TIPT Comparison
Compare ANAB & TIPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- TIPT
- Stock Information
- Founded
- ANAB 2005
- TIPT 2007
- Country
- ANAB United States
- TIPT United States
- Employees
- ANAB N/A
- TIPT N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- TIPT Property-Casualty Insurers
- Sector
- ANAB Health Care
- TIPT Finance
- Exchange
- ANAB Nasdaq
- TIPT Nasdaq
- Market Cap
- ANAB 759.5M
- TIPT 808.7M
- IPO Year
- ANAB 2017
- TIPT 2007
- Fundamental
- Price
- ANAB $19.59
- TIPT $21.36
- Analyst Decision
- ANAB Buy
- TIPT
- Analyst Count
- ANAB 10
- TIPT 0
- Target Price
- ANAB $37.75
- TIPT N/A
- AVG Volume (30 Days)
- ANAB 589.1K
- TIPT 129.2K
- Earning Date
- ANAB 05-05-2025
- TIPT 04-30-2025
- Dividend Yield
- ANAB N/A
- TIPT 1.12%
- EPS Growth
- ANAB N/A
- TIPT 107.58
- EPS
- ANAB N/A
- TIPT 1.20
- Revenue
- ANAB $111,872,000.00
- TIPT $2,042,059,000.00
- Revenue This Year
- ANAB N/A
- TIPT N/A
- Revenue Next Year
- ANAB $44.69
- TIPT N/A
- P/E Ratio
- ANAB N/A
- TIPT $17.81
- Revenue Growth
- ANAB 387.20
- TIPT 15.66
- 52 Week Low
- ANAB $12.21
- TIPT $15.60
- 52 Week High
- ANAB $41.31
- TIPT $26.90
- Technical
- Relative Strength Index (RSI)
- ANAB 48.98
- TIPT 44.82
- Support Level
- ANAB $18.51
- TIPT $21.03
- Resistance Level
- ANAB $21.52
- TIPT $21.79
- Average True Range (ATR)
- ANAB 1.16
- TIPT 0.67
- MACD
- ANAB -0.26
- TIPT -0.06
- Stochastic Oscillator
- ANAB 26.97
- TIPT 40.63
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About TIPT Tiptree Inc.
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.